Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2014, Article ID 608585, 4 pages
http://dx.doi.org/10.1155/2014/608585
Case Report

Letrozole Induced Hypercalcemia in a Patient with Breast Cancer

1Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Selcuk University, 42131 Konya, Turkey
2Department of Internal Medicine, Faculty of Medicine, Selcuk University, 42131 Konya, Turkey
3Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Selcuk University, 42131 Konya, Turkey

Received 27 February 2014; Accepted 30 April 2014; Published 15 May 2014

Academic Editor: Katsuhiro Tanaka

Copyright © 2014 Suleyman Hilmi Ipekci et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Santarpia, C. A. Koch, and N. J. Sarlis, “Hypercalcemia in cancer patients: pathobiology and management,” Hormone and Metabolic Research, vol. 42, no. 3, pp. 153–164, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. G. P. Arumugam, S. Sundravel, P. Shanthi, and P. Sachdanandam, “Tamoxifen flare hypercalcemia: an additional support for gallium nitrate usage,” Journal of Bone and Mineral Metabolism, vol. 24, no. 3, pp. 243–247, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. Z. Nikolić-Tomǎević, S. Jelic, I. Popov, D. Radosavljeví, and L. Mitroví, “Tumor “flare” hypercalcemia—an additional indication for bisphosphonates?” Oncology, vol. 60, no. 2, pp. 123–126, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Kuroi, T. Yamashita, T. Aruga et al., “Flare hypercalcemia after letrozole in a patient with liver metastasis from breast cancer: a case report,” Journal of Medical Case Reports, vol. 5, article 495, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. I. E. Smith and M. Dowsett, “Aromatase inhibitors in breast cancer,” The New England Journal of Medicine, vol. 348, no. 24, pp. 2431–2442, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. C. B. Confavreux, A. Fontana, J. P. Guastalla, F. Munoz, J. Brun, and P. D. Delmas, “Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates,” Bone, vol. 41, no. 3, pp. 346–352, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. P. D. Delmas, “Biochemical markers of bone turnover for the clinical investigation of osteoporosis,” Osteoporosis International, vol. 3, no. 1, pp. 81–86, 1993. View at Google Scholar · View at Scopus
  8. S. Nussey and S. Whitehead, “The parathyroid glands and vitamin D,” in Endocrinology: An Integrated Approach, Chapter 5, BIOS Scientific Publishers, Oxford, UK, 2001, http://www.ncbi.nlm.nih.gov/books/NBK24/. View at Google Scholar
  9. A. G. Need, M. Horowitz, H. A. Morris, and B. E. C. Nordin, “Vitamin D status: effects on parathyroid hormone and 1,25- dihydroxyvitamin D in postmenopausal women,” The American Journal of Clinical Nutrition, vol. 71, no. 6, pp. 1577–1581, 2000. View at Google Scholar · View at Scopus
  10. A. F. Stewart, “Clinical practice. Hypercalcemia associated with cancer,” The New England Journal of Medicine, vol. 352, no. 4, pp. 373–379, 2005. View at Google Scholar · View at Scopus
  11. J. F. Seymour and R. F. Gagel, “Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas,” Blood, vol. 82, no. 5, pp. 1383–1394, 1993. View at Google Scholar · View at Scopus
  12. G. A. Clines and T. A. Guise, “Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone,” Endocrine-Related Cancer, vol. 12, no. 3, pp. 549–583, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. M. S. Bendre, A. G. Margulies, B. Walser et al., “Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-κB ligand pathway,” Cancer Research, vol. 65, no. 23, pp. 11001–11009, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Rabaglio, Z. Sun, K. N. Price et al., “Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial,” Annals of Oncology, vol. 20, no. 9, pp. 1489–1498, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Morin, L. M. Lix, M. Azimaee, C. Metge, P. Caetano, and W. D. Leslie, “Mortality rates after incident non-traumatic fractures in older men and women,” Osteoporosis International, vol. 22, no. 9, pp. 2439–2448, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. O. Rusz and Z. Kahán, “Bone homeostasis and breast cancer: implications for complex therapy and the maintenance of bone integrity,” Pathology & Oncology Research, vol. 19, no. 1, pp. 1–10, 2013. View at Publisher · View at Google Scholar
  17. X. L. Xu, W. L. Gou, A. Y. Wang et al., “Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years?” Journal of Translational Medicine, vol. 11, article 303, 2013. View at Publisher · View at Google Scholar
  18. V. R. Jagtap and J. V. Ganu, “Effect of antiresorptive therapy on urinary hydroxyproline in postmenopausal osteoporosis,” Indian Journal of Clinical Biochemistry, vol. 27, no. 1, pp. 90–93, 2012. View at Publisher · View at Google Scholar · View at Scopus